The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Obesity risk begins early—even before birth—driven by maternal BMI, formula feeding, poor diets, and family lifestyle. Early ...

NIH-funded AI model predicts cancer survival from single-cell tumour data: Bethesda, Maryland Friday, April 24, 2026, 17:00 Hrs [IST] In a National Institutes of Health (NIH)-fund ...

In a National Institutes of Health (NIH)-funded study, researchers developed a cancer assessment tool that can identify ...

Weill Cornell Medicine researchers have demonstrated, for the first time, that Hodgkin lymphoma cancer cells from patient ...

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells ...

Explore luminescence screening assays for drug discovery, including luciferase and ATP assays. Learn the principles, formats, ...

Equinor Canada Ltd. has issued an expression of interest from qualified contractors for a mobile offshore drilling unit for ...

That’s why today, the Bezos Earth Fund announced $34 million to advance breakthrough materials for the fashion and textile industry. Working with scientists and researchers across the United States, ...

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...

A new study by researchers at Fox Chase Cancer Center focusing on pancreatic cancer has shown that a new scoring system can ...